2023 U.S.-Booked Air Volume: $42.1 million
Consolidated Global TMC: BCD
British pharmaceutical giant AstraZeneca in 2023 spent about
$42.1 million on U.S.-booked air travel, according to a BTN estimate, up from
2022.
The company's 2023 emissions related to its global business
travel totaled about 155,400 metric tons of carbon dioxide equivalent, up from
about 145,800 the year prior but less than half the 327,100 logged in 2019.
AstraZeneca has set a goal that half of its business travel
suppliers by spend by 2025 should have set science-based targets regarding
their emissions. At the end of 2023, 32 percent of its business travel
suppliers had done so, leaving the company on track to meet the objective.
The company in 2023 and 2024 agreed in separate deals to
acquire a string of pharmaceutical companies, including CinCor Pharma,
Icosavax, Gracell Biotechnologies, Amolyt Pharma and Fusion Pharmaceuticals.
AstraZeneca's total 2023 revenue increased about 3 percent year
over year to $45.8 billion. The company had 89,900 employees at the end of
2023, up from 83,500 in 2022.